Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.
Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL. Murphy GP, et al. Among authors: tjoa ba. Prostate. 1999 Jan 1;38(1):73-8. doi: 10.1002/(sici)1097-0045(19990101)38:1<73::aid-pros9>3.0.co;2-v. Prostate. 1999. PMID: 9973112 Clinical Trial.
Dendritic cell-based immunotherapy of prostate cancer.
Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, Murphy GP. Salgaller ML, et al. Among authors: tjoa ba. Crit Rev Immunol. 1998;18(1-2):109-19. doi: 10.1615/critrevimmunol.v18.i1-2.120. Crit Rev Immunol. 1998. PMID: 9419453 Clinical Trial.
Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).
Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP. Salgaller ML, et al. Among authors: tjoa ba. Prostate. 1998 May;35(2):144-51. doi: 10.1002/(sici)1097-0045(19980501)35:2<144::aid-pros8>3.0.co;2-j. Prostate. 1998. PMID: 9568678 Clinical Trial.
GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial.
Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, Troychak MJ, Boynton AL, Murphy GP. Simmons SJ, et al. Among authors: tjoa ba. Prostate. 1999 Jun 1;39(4):291-7. doi: 10.1002/(sici)1097-0045(19990601)39:4<291::aid-pros10>3.0.co;2-9. Prostate. 1999. PMID: 10344219 Clinical Trial.
Vaccine therapy for prostate cancer.
Tjoa BA, Elgamal AA, Murphy GP. Tjoa BA, et al. Urol Clin North Am. 1999 May;26(2):365-74, ix. doi: 10.1016/s0094-0143(05)70076-8. Urol Clin North Am. 1999. PMID: 10361559
Follow-up evaluation of a phase II prostate cancer vaccine trial.
Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP. Tjoa BA, et al. Prostate. 1999 Jul 1;40(2):125-9. doi: 10.1002/(sici)1097-0045(19990701)40:2<125::aid-pros8>3.0.co;2-y. Prostate. 1999. PMID: 10386473 Clinical Trial.
28 results